Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00528541




Registration number
NCT00528541
Ethics application status
Date submitted
10/09/2007
Date registered
12/09/2007
Date last updated
16/12/2011

Titles & IDs
Public title
Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia
Scientific title
Secondary ID [1] 0 0
MedAff-BTX-0616
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Spasmodic Torticollis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - botulinum toxin type A
Treatment: Other - botulinum toxin type A

Active comparator: BOTOX® - botulinum toxin type A (BOTOX®)

Active comparator: Dysport® - botulinum toxin type A (Dysport®)


Treatment: Other: botulinum toxin type A
200 Units at Visit 1 (Day 1)

Treatment: Other: botulinum toxin type A
750 Units at Visit 1 (Day 1)
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Dysphagia Incidence Over 10 Weeks
Timepoint [1] 0 0
10 weeks
Secondary outcome [1] 0 0
Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score at Week 4
Timepoint [1] 0 0
Baseline, Week 4
Secondary outcome [2] 0 0
Physician Assessment of Cervical Dystonia Severity at Week 4
Timepoint [2] 0 0
Baseline, Week 4
Secondary outcome [3] 0 0
Global Assessment of Benefit by Physician at Week 4
Timepoint [3] 0 0
Week 4
Secondary outcome [4] 0 0
Global Assessment of Benefit by Patient at Week 4
Timepoint [4] 0 0
Week 4
Secondary outcome [5] 0 0
Patient Assessment of Need for Retreatment at Week 4
Timepoint [5] 0 0
Baseline, Week 4
Secondary outcome [6] 0 0
Patient Visual Analog Assessment of Pain at Week 4
Timepoint [6] 0 0
Baseline, Week 4
Secondary outcome [7] 0 0
Physician Comparison of Benefit to Previous Injections at Week 10
Timepoint [7] 0 0
Week 10
Secondary outcome [8] 0 0
Patient Comparison of Benefit to Previous Injections at Week 10
Timepoint [8] 0 0
Week 10

Eligibility
Key inclusion criteria
* Diagnosed with cervical dystonia/spasmodic torticollis for at least 18 months
* Successfully treated previously with botulinum toxin type A
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Breast feeding, pregnant or could become pregnant
* Surgery or spinal cord stimulation for cervical dystonia
* Previous injections of phenol, alcohol for cervical dystonia

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/09/2007
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/09/2009
Sample size
Target
Accrual to date
Final
145
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
- Adelaide
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment outside Australia
Country [1] 0 0
Croatia
State/province [1] 0 0
Zagreb
Country [2] 0 0
Italy
State/province [2] 0 0
Rome
Country [3] 0 0
Poland
State/province [3] 0 0
Krakow
Country [4] 0 0
Turkey
State/province [4] 0 0
Istanbul

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Allergan
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Allergan
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT00528541